ArticleJCI insight2016
B cells from African American lupus patients exhibit an activated phenotype.
Article in JCI insight, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 57 citations in OpenAlex.
- Outcome of Patients With Lupus Nephritis Treated With an Anti-CD40 Monoclonal Antibody According to Kidney Biopsy Features.Arthritis & rheumatology (Hoboken, N.J.) · 2025Trial
- Trial
- Autoantibody-positive healthy individuals with lower lupus risk display a unique immune endotype.The Journal of allergy and clinical immunology · 2020Trial
- Ethnicity affects relapse-free survival in immunemediated thrombotic thrombocytopenic purpura.Haematologica · 2026Article
- GLUT1-mediated glucose flux constrains autoreactive but not foreign antigen-specific B-cell responses.Journal of immunology (Baltimore, Md. : 1950) · 2026Article
- Interferon signatures fuel B cell hyperactivity and plasmablast expansion in systemic lupus erythematosus.Journal of autoimmunity · 2025Article
- Cytokines unveiled: their impact on oral and multisystem features of lupus erythematosus.Frontiers in immunology · 2025Review
- B cell-extrinsic and intrinsic factors linked to early immune repletion after anti-CD20 therapy in patients with multiple sclerosis of African ancestry.Frontiers in immunology · 2025Article
- IFN-associated B cell hyperactivity is highly enriched in SLE patients harboring Sm/RNP antibodies.bioRxiv : the preprint server for biology · 2024Article
- Ancestry-based differences in the immune phenotype are associated with lupus activity.JCI insight · 2023Article
- Pathogenesis of autoimmune disease.Nature reviews. Nephrology · 2023Review
- Targeted Therapy for SLE-What Works, What Doesn't, What's Next.Journal of clinical medicine · 2023Review
- Molecular pathways identified from single nucleotide polymorphisms demonstrate mechanistic differences in systemic lupus erythematosus patients of Asian and European ancestry.Scientific reports · 2023Article
- Longitudinal trends of systemic lupus erythematous hospitalizations in the United States: a two-decade population-based study.Clinical rheumatology · 2023Article
- Distinct genome-wide DNA methylation and gene expression signatures in classical monocytes from African American patients with systemic sclerosis.Clinical epigenetics · 2023Article
- Understanding humoral immunity and multiple sclerosis severity in Black, and Latinx patients.Frontiers in immunology · 2023Review
- Neuron-binding antibody responses are associated with Black ethnicity in multiple sclerosis during natalizumab treatment.Brain communications · 2023Article
- ATR-mediated DNA damage responses underlie aberrant B cell activity in systemic lupus erythematosus.Science advances · 2022Article
- Race, rituximab, and relapse in TTP.Blood · 2022Article
- HLA Homozygosity and Likelihood of Sensitization in Kidney Transplant Candidates.Transplantation direct · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Systemic lupus erythematosus (SLE) is a complex systemic autoimmune disease driven by both innate and adaptive immune cells. African Americans tend to present with more severe disease at an earlier age compared with patients of European ancestry. In order to better understand the immunological differences between African American and European American patients, we analyzed the frequencies of B cell subsets and the expression of B cell activation markers from a total of 68 SLE patients and 69 normal healthy volunteers. We found that B cells expressing the activation markers CD86, CD80, PD1, and CD40L, as well as CD19
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.